Intuitive Surgical, Inc. — FY 2011 Form 10-K
Business context and reporting period: The filing covers the fiscal year ended December 31, 2011; the company reports as one operating segment. Intuitive designs, manufactures, and sells da Vinci robotic surgical systems, instruments and accessories, and related service. Its business combines capital sales with recurring revenue tied to system use and service contracts.
Financial and operating performance
| Metric | FY 2011 | FY 2010 | Change |
|---|---|---|---|
| Revenue | $1,757.3 million | $1,413.0 million | +24% |
| Gross profit / margin | $1,273.8 million / 72% | $1,030.0 million / 73% | Margin down 1 percentage point |
| Operating income / margin | $694.8 million / 39% | $555.2 million / 40% | Income +25% |
| Net income / diluted EPS | $495.1 million / $12.32 | $381.8 million / $9.47 | Net income +30% |
| Operating cash flow | $677.6 million | $545.8 million | +24% |
| Cash, cash equivalents and investments | $2,171.8 million | $1,608.9 million | +$562.9 million |
| Total assets / total liabilities | $3,063.1 million / $417.5 million | $2,390.4 million / $353.0 million | — |
- Product revenue was $1,478.9 million; service revenue was $278.4 million. Instruments and accessories revenue rose 33% to $701.1 million, while system revenue rose 18% to $777.8 million.
- Recurring revenue increased 30% to $979.5 million, or 56% of revenue, from $752.7 million, or 53%, in 2010. The installed base grew to 2,132 systems from 1,752; approximately 360,000 procedures were performed, up about 29%.
- FY 2011 diluted EPS was $12.32. The effective tax rate was approximately 30.2%, versus 33.3% in 2010.
- At year-end, current assets were $1,466.3 million and current liabilities were $320.6 million. The balance sheet lists no separate interest-bearing debt line; long-term liabilities were $96.9 million, primarily income taxes.
- Investing cash outflow was $479.0 million and financing cash outflow was $12.4 million. The company repurchased $331.8 million of stock; employee stock programs generated $260.6 million. Capital expenditures and intellectual-property purchases totaled $82.9 million.
Fourth-quarter snapshot
FY 2011 Q4 revenue was $496.8 million, gross profit $362.9 million, and net income $151.2 million; diluted EPS was $3.75. In Q4 2010, revenue was $389.3 million, gross profit $282.1 million, net income $121.2 million, and diluted EPS $3.02. The filing notes historical seasonality, with procedure volume and system sales tending to be higher in Q4.
Material changes and management commentary
- Growth reflected broader da Vinci procedure adoption, a larger installed base and higher utilization. Hysterectomy volume increased from about 110,000 cases in 2010 to 146,000 in 2011; prostatectomy volume rose from about 98,000 to 113,000. Other procedures grew more than 40% to approximately 101,000.
- System sales increased to 534 from 441; 495 systems sold in 2011 were da Vinci Si models. Product gross margin declined to 74.1% from 75.0%, partly due to lower-margin Skills Simulators. Service gross margin improved to 63.7% from 61.7%.
- SG&A increased 22% to $438.8 million and R&D increased 21% to $140.2 million, reflecting business expansion, staffing and product development. Management expects substantial R&D investment and expenses to continue increasing.
- Management believes cash, investments and operating cash generation will fund foreseeable liquidity needs and future growth. No specific revenue, earnings or procedure-volume guidance is provided.
- New or expanded offerings included Firefly imaging, Skills Simulator, Single-Site instruments and the EndoWrist One Vessel Sealer. The company received U.S. clearance for Single-Site laparoscopic cholecystectomy and the vessel sealer in December 2011.
Risks, contingencies and unusual items
- Adoption depends on clinical acceptance, training, procedure economics and hospital capital budgets; system sales cycles are long and results are seasonal. Competition, economic conditions and reimbursement constraints could limit demand.
- Healthcare policy risks include a 2.3% U.S. medical-device excise tax scheduled to begin in 2013 and possible Medicare payment reductions of up to 2% starting in 2013. Japan reimbursement approval had not been obtained; Japan represented about 2% of 2011 revenue.
- The FDA issued a Form 483 after a July 2010 inspection concerning complaint handling and manufacturing/inspection handling. The company proposed corrective actions; a January 2012 Sunnyvale audit resulted in no Form 483, but effectiveness of corrective actions remained subject to follow-up.
- A securities class action and consolidated shareholder derivative actions remained pending. The class-action dismissal motion had not yet been heard; the company said outcomes could not be estimated and recorded no liability. Management believed resolution was unlikely to materially affect the company, based on information then available.
- $16.4 million of auction-rate securities remained illiquid after failed auctions; fair value was below cost, and further losses or impairment were possible. The company also disclosed $98.1 million of gross unrecognized tax benefits at year-end.
- Purchase commitments and obligations totaled $225.5 million, mostly due within one year; the company said many purchase orders were cancellable or adjustable. Potential milestone payments and uncertain tax-benefit payments were excluded from the contractual-obligations table. No significant off-balance-sheet arrangements were reported.
- Other notable exposures include sole- or single-source components, product liability and recalls, foreign exchange, cybersecurity, intellectual-property disputes, and regulatory approvals. The company reported no dividend and retained earnings for business use.
Important facts for investors to verify
- Whether procedure growth and recurring revenue continue to support system utilization and margins, particularly as hysterectomy and prostatectomy account for a large share of procedures.
- Evidence of sustained adoption and economics for newer products and emerging procedures, including their effect on product mix and gross margin.
- Progress on FDA corrective actions, future inspections, and the status and potential exposure of the securities and derivative lawsuits.
- Liquidity and valuation developments for auction-rate securities, and outcomes of tax audits or changes in the effective tax rate.
- Whether reimbursement, healthcare policy changes, hospital budgets, and international market conditions affect demand; assess the company’s statements as forward-looking and subject to the risks described in the filing.